Bill Avery joined Kisbee in October 2021 as the Senior Vice President of Translational Development, bringing more than 22 years of industry experience in preclinical and translational development. Bill has worked on more than 20 programs, including small molecules, biologics, gene therapy, and cellular therapies, through IND and into early clinical development. Most recently, he was the Senior Vice President of Nonclinical Development at Xilio Therapeutics. Prior to joining Xilio, Bill held roles of increasing responsibility within Preclinical and Translational Development at Lyndra Therapeutics, Life BioSciences, Momenta, CombinatoRx and Millennium. He received his B.S. in Veterinary Sciences from the University of Massachusetts, Amherst and his PhD in Pharmacology and Toxicology from A.T. Still University.